ReviewBioactive materials2027
Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.
Review in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transarterial embolization and transcatheter arterial chemoembolization are important locoregional therapies for intermediate-to-advanced hepatocellular carcinoma (HCC), yet their efficacy remains constrained by the performance limitations of embolic materials. Although traditional embolic materials have been widely used in clinical practice, they commonly suffer from poor drug loading capacity, uncontrollable release kinetics, suboptimal spatial selectivity, and unpredictable embolization duration, making it difficult to meet the demands of precision and combination therapy. In recent years, advanced biomaterials, represented by hydrogels and microspheres, have provided new approaches to improving the controllability and comprehensive efficacy of interventional embolization therapy through the optimization of material properties and functional expansion. This review provides an overview of the basis and limitations of the clinical application of traditional embolic materials, focuses on the embolization performance and functional advantages of biomaterials, and discusses their potential for combination with systemic therapy. In addition, we discuss the challenges in clinical translation of embolic drug-delivery systems and future directions, aiming to inspire further research on precision embolization therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.